NLRP3 and rheumatoid arthritis: MCC950 has been used in phase II clinical trials in patients with RA, in which the activation of the NLRP3 inflammasome plays a role (183), however MCC950 caused liver toxicity (184), sparking the pursuit of NLRP3 inhibitors with enhanced pharmacokinetic properties.